PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 07:30 ET
|
PDS Biotechnology Corporation
Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023Biomarker data from VERSATILE-002 to be...
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
August 14, 2023 07:00 ET
|
PDS Biotechnology Corporation
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates initiating the VERSATILE-003 trial in...
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
August 07, 2023 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
August 02, 2023 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023
July 25, 2023 08:00 ET
|
PDS Biotechnology Corporation
Data from ongoing VERSATILE-002 trial to highlight HPV16-specific T cell responses in subjects receiving PDS0101 and KEYTRUDA® for recurrent or metastatic HPV16-positive head and neck cancer FLORHAM...
PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023
July 17, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301
July 11, 2023 08:00 ET
|
PDS Biotechnology Corporation
Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in CanadaPDS Biotech’s proprietary combination of Versamune® based PDS0101 and PDS0301 with an immune checkpoint...
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023 16:05 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech”), a clinical-stage immunotherapy company developing a growing pipeline of targeted...
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
June 20, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corp. (NASDAQ: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and...
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer
June 14, 2023 08:00 ET
|
PDS Biotechnology Corporation
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed...